GWP.L Share News (GWP)

BUZZ-GW Pharmaceuticals Plc: Drug could have potential in autism - Telegraph

** Cannibis-based drugmaker's U.S.-listed shares up 11.11 pct at $76.29, snapping a three-day streak of declines ** Company putting together "building blocks" of a research program to see if a cannabis-based medicine could treat symptoms of autism, CEO told The Telegraph (http://bit.ly/1pUW

GW Pharmaceuticals blames R&D spending for wider losses

Cannabis-based drug maker GW Pharmaceuticals blamed higher research and development costs for higher annual losses, knocking its shares. GW, whose flagship cannabinoid prescription drug Sativex is approved in 27 countries outside the US to treat spasticity due to multiple sclerosis, said pre-tax los

GW Pharmaceuticals Starts Trial On Epidiolex For Dravet Syndrome

GW Pharmaceuticals Epidiolex Gets Orphan Drug Designation From EMA

BUZZ-GW Pharmaceuticals Plc: Bowel drug misses main goal in study

** U.S.-listed shares of the maker of cannabis-based drugs down 4 pct at $68.50 ** Company said its experimental drug failed to meet the main goal in a mid-stage study in patients with an inflammatory bowel disorder ** The drug, GWP42003, is being tested in patients with ulcerative c

GW Pharmaceuticals Says Phase 2a Ulcerative Colitis Data Positive

UPDATE 1-UK cost agency rejects British company GW's cannabis drug

* NICE says modest benefit of Sativex does not justify use * GW says "terrible shame" drug unavailable in home country * Sativex already approved in more than 20 countries * GW shares fall 1.6 percent in early trading (Adds share price decline) By Ben Hirschler LON

UK cost agency rejects British company GW's cannabis drug

* NICE says modest benefit of Sativex does not justify use * GW says "terrible shame" drug unavailable in home country * Sativex already approved in more than 20 countries By Ben Hirschler LONDON, Oct 8 (Reuters) - A pioneering cannabis drug developed by British firm GW Ph

DIRECTOR DEALINGS: GW Pharmaceuticals Chairman Gifts Shares To Charity

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

Sector movers: Shire and AZN lead pharma stocks lower on M&A risk

The pharmaceutical sector dropped on Wednesday on the back of fears about risks to mergers and acquisitions (M&A) activity, with Shire sinking sharply. Concerns that stricter rules on so-called 'tax inversion' in the US could scupper Abbvie's £32bn takeover of London-listed Shire dented the latter'

GW Pharmaceuticals Loss Widens As Higher Costs Offset Revenue Rise

UK MORNING BRIEFING: Shares Open Lower Amid Ukraine Tensions

UK Earnings, Trading Statements Calendar - Week Ahead